Trial of Simvastatin for the Treatment of Severe Asthma

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Severe Asthma

In brief

This purpose of this clinical trial is to determine if a statin drug, Simvastatin, added to inhaled corticosteroids and bronchodilators can reduce systemic and airway inflammation, improve lung function and symptoms, and reduce acute exacerbations in patients with severe asthma who are already on controller inhaler therapy. This proposed investigator-initiated, single-center, early Phase II, cross-over, randomized clinical trial, titled "Randomized Trial of Simvastatin for the Treatment of Severe Asthma", will be conducted at the University of California, Davis Medical Center (UCDMC) in Sacramento, CA. This trial will evaluate Simvastatin for treatment of asthma in subjects with severe asthma (as defined by the American Thoracic Society (ATS)), who are already taking inhaler controller therapy. The investigators plan to enroll 24 patients with severe allergic asthma. The investigators hypothesize that treatment with Simvastatin 40 mg (administered once daily) will not only improve indicators of airway and systemic allergic/Th2 inflammation, but will also reduce acute exacerbations and improve lung function. All patients will be on standard controller therapy including appropriate doses of inhaled corticosteroids and long-acting bronchodilators.

Key facts

Study ID

NCT02433535

Run by

University of California, Davis

People needed

0

Starts

2013-12-01

Expected to finish

2017-08-22

Last updated by the study team

2017-09-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• statin-naïve adults >18 years old with the ATS definition of severe asthma,
• on ICS and LABA,
• confirmation of allergic asthma (serum IgE >100 kU/L, positive radioallergosorbent test (RAST) panel, and/or peripheral blood absolute eosinophil count of ≥700/mm3),
• clinically stable for 4 weeks.

You may not qualify if…

• baseline FEV1 <30% predicted,
• current smokers or ex-smokers with >5 pack-years of smoking history,
• pregnant women, nursing/lactating mothers, or women of childbearing potential who are actively attempting to become pregnant,
• nasal or sinus surgery or trauma within 3 months of study participation,
• ischemic heart disease,
• liver disease, and
• the concurrent use of the following medications (amiodarone, verapamil, diltiazem, gemfibrozil, cyclosporine, antifungal azoles (itraconazole, ketoconazole, or voriconazole), and danazol.

Where it is running

• CTSC Clinical Research Center — Sacramento, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.